Antares Pharma (ATRS) 3.07 $ATRS
Drug-Exposure Limitations of Oral Methotrexate at Doses Greater Than or Equal to 15 Mg May Be Overcome with Subcutaneous Administration
Business Wire - Thu Apr 17, 6:01AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the Annals of the Rheumatic Diseases has published results from an open-label, head-to-head randomized, crossover study comparing the relative bioavailability, safety and tolerability of OTREXUP to oral methotrexate (MTX) in adult patients with rheumatoid arthritis (RA).
Antares Pharma Announces Additional Patent Coverage for OTREXUP
Business Wire - Wed Apr 16, 6:01AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.S. Patents RE44846 and RE44847. These patents are reissued versions of U.S. Patents 7,744,582, and 7,776,015. Tracing back to inventions made in the late 1990's, the patents capture innovations in the field of auto injectors that originally established Antares Pharma's position as a leader and innovator in medical injection device technology. Importantly, these patents add protection to OTREXUP as well as Antares' pipeline products. Antares is taking steps to supplement the current Orange Book listings related to OTREXUP.
Global Insulin Delivery Devices Market to 2019
M2 - Wed Apr 09, 8:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h59w23/insulin_delivery) has announced the addition of the "Insulin Delivery Devices Market to 2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers" report to their offering. The global insulin delivery devices market was valued at $8.8 billion in 2012 and is forecast to reach $13.8 billion by 2019, at a CAGR of 7%. Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers Growth in developed economies such as the US and Europe is attributed to an increasing preference for insulin pumps and the uptake of technical advances such as artificial pancreas devices. Supply-side initiatives aim to develop artificial pancreas devices that closely mimic the pancreas by using rapid-acting insulin and multiple hormone-secreting devices for the effective control of blood glucose. The growth in developing economies is attributed to the high prevalence of diabetes and low penetration of insulin delivery devices in these countries. Collaborations among companies and research foundations such as the Juvenile Diabetes Research Foundation (JDRF) help foster innovation in the diabetes care devices market. Many of these collaborations aim to develop artificial pancreas devices that can effectively replace the pancreas, ensuring the effective management of diabetes. Emerging economies such as India and China are expected to grow at the fastest pace during the 2012-2019 forecast period. While developed economies will witness increasing uptake of technically advanced devices, emerging economies will continue to see increasing uptake for conventional insulin delivery devices such as insulin pens, due to their lower cost." Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Diabetes - Disease Overview 4 Diabetes - Epidemiology 5 Global Insulin Delivery Devices Market: Device Overview 6 Global Insulin Delivery Devices Market: Market Characterization 7 Global Insulin Delivery Devices Market: Segment Analysis and Forecasts 8 Global Insulin Delivery Devices Market: Country Analysis and Forecasts 9 Global Insulin Delivery Devices Market: Reimbursement System 10 Global Insulin Delivery Devices Market: Competitive Landscape Companies Mentioned - Abbott Laboratories - Animas - Antares Pharma - Asante Solutions - Becton, Dickinson and Company - Bioject Medical Technologies - Eli Lilly - F. Hoffmann-La Roche - Injex - Equidyne Systems - Insulet - Medtronic - Novo Nordisk (Subsidiary of Novo A/S) - Owen Mumford - Sanofi - Shanghai Fosun Pharmaceutical - Tandem Diabetes Care - Tonghua Dongbao Pharmaceutical - Ypsomed For more information visit http://www.researchandmarkets.com/research/h5...n_delivery
Technical Roundup on Health Care Sector Stocks -- Research on Becton Dickinson and Co., Antares Pharma, Hooper Holmes, and Catamaran
PR Newswire - Thu Apr 03, 7:28AM CDT
On Wednesday, April 02, 2014, the NASDAQ Composite finished at 4,276.46, up 0.20%. The Dow Jones Industrial Average closed the session at 16,573.00, up 0.24% and the S&P 500 ended the day at 1,890.90, higher by 0.29%. The gains were broad based with eight out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index finished the day at 684.15, up 0.36%, and the index has gained 7.11% in the previous three months. Investor-Edge has initiated coverage on the following equities: Becton Dickinson and Co. (NYSE: BDX), Antares Pharma Inc. (NASDAQ: ATRS), Hooper Holmes Inc. (NYSE MKT: HH) and Catamaran Corp. (NASDAQ: CTRX). Free technical research on BDX, ATRS, HH and CTRX can be downloaded upon signing up at:
Financial Results, Launches, Adjusted Conversion Rates, Upcoming Presentations, and Stock Movements - Analyst Notes on AbbVie, Chemed, Antares Pharma, Magellan Health Services, and Natus Medical
PR Newswire - Thu Apr 03, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding AbbVie Inc. (NYSE: ABBV), Chemed Corp. (NYSE: CHE), Antares Pharma Inc. (NASDAQ: ATRS), Magellan Health Services Inc. (NASDAQ: MGLN), and Natus Medical Inc. (NASDAQ: BABY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Antares Pharma secures second milestone payment from LEO Pharma following launch of OTREXUP for treating psoriasis
M2 - Thu Mar 13, 6:05AM CDT
Pharmaceutical company Antares Pharma (NasdaqCM:ATRS) said on Wednesday that it has received a second milestone payment of USD5m under its dermatology partnership with LEO Pharma.
Antares Pharma Reports Fourth Quarter and Full Year 2013 Operating and Financial Results
Business Wire - Thu Mar 13, 6:01AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the fourth quarter and full year ended December 31, 2013.
Antares Pharma Receives Second Milestone Payment from LEO Pharma in OTREXUP Collaboration
Business Wire - Wed Mar 12, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the receipt of a second milestone payment of $5 million from LEO Pharma. The milestone payment was received in connection with the launch of OTREXUP and the achievement of a specific percentage of patient lives covered by managed care organizations. To date, Antares has received $10 million in milestone payments from LEO Pharma.
Medac Pharma, Inc. Announces the Issuance of U.S. Patent for Treating Autoimmune Diseases with Concentrated Methotrexate Solutions of More Than 30 mg/ml
PR Newswire - Tue Mar 11, 9:17AM CDT
Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announces the issuance, via its parent company, medac GmbH, of U.S. patent 8,664,231 (the '231 patent) by the United States Patent and Trademark Office. The patent, entitled "Concentrated Methotrexate Solutions," is directed to a method for the treatment of inflammatory autoimmune diseases by subcutaneously administering methotrexate (MTX) at a concentration of more than 30 mg/ml.
Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry
M2 - Tue Mar 11, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qpswzp/testosterone) has announced the addition of the "Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The global and the US markets are further analyzed by the following Product Segments: - Topicals - Patches - Others Company profiles are primarily based on public domain information including company URLs. The report profiles 30 companies including many key and niche players such as: - AbbVie Inc. - Acrux Ltd. - Actavis, Inc. - Antares Pharma, Inc. - Auxilium Pharmaceuticals, Inc. - Bayer HealthCare Pharmaceuticals - Clarus Therapeutics Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview 3. Product Landscape 4. Testosterone Deficiency And Trt - An Overview 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Europe 4. Asia-Pacific 5. Latin America 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 30 (including Divisions/Subsidiaries - 36) - The United States (20) - Canada (4) - Japan (1) - Europe (7) - France (1) - Germany (1) - The United Kingdom (2) - Italy (1) - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (4) For more information visit http://www.researchandmarkets.com/research/qp...estosteron
Antares Pharma Announces LEO Pharma's Launch of OTREXUP (Methotrexate) Injection to Dermatologists for Adults with Psoriasis
Business Wire - Mon Mar 10, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced LEO Pharma's launch of OTREXUPto Dermatologists, the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Antares Pharma to Host Fourth Quarter 2013 Operating and Financial Results Conference Call
Business Wire - Thu Mar 06, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its fourth quarter 2013 financial results before the market opens on Thursday, March 13, 2014, and host a conference call shortly thereafter at 8:30 a.m. ET (Eastern Time) to discuss the results. Paul K. Wotton, Ph.D., President and Chief Executive Officer, and Robert F. Apple, EVP, Chief Financial Officer, and President of the Parenteral Products Division, will host the call.
Antares Pharma to Present at the Cowen and Company 34th Annual Healthcare Conference
Business Wire - Wed Feb 26, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 34th Annual Healthcare Conference on Wednesday March 5, 2014 at 8:00 am Eastern Time.
Today's Biggest Biotech Stories: Antares Pharma Inc., BioCryst Pharmaceuticals Inc., and Raptor Phar
George Budwell, The Motley Fool - Motley Fool - Thu Feb 20, 9:02AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! It's time to check in...
Antares Pharma Announces Positive Results from the VIBEX QuickShot Pharmacokinetic Study in Testosterone Deficient Men
Business Wire - Thu Feb 20, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from a multi-center phase 2 clinical study evaluating the pharmacokinetic profile of testosterone enanthate administered once-weekly by subcutaneous injection at doses of 50 mg and 100 mg using the VIBEX QuickShot auto injector in testosterone deficient adult males.
Antares Pharma, Inc. [ATRS] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Wed Feb 19, 9:00AM CST
What:
Antares Pharma to Participate in the 2014 RBC Capital Markets' Global Healthcare Conference
Business Wire - Wed Feb 19, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that LeRoux Jooste, Senior Vice President and General Manager Pharmaceuticals, will participate in the RBC Capital Markets' Global Healthcare Conference on Wednesday February 26, 2014 at 11:00 am Eastern Time.
2013 Report on the International North America Injectable Drug Delivery Market - Forecasts to 2017
M2 - Thu Jan 23, 5:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/3brffr/north_america) has announced the addition of the "2013 Report on the International North America Injectable Drug Delivery Market - Forecasts to 2017" report to their offering. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices. The major markets covered in this report are United States and Canada. The United States accounted for the largest market of the North American injectable drug delivery technologies market in the year 2012. However, Canada is expected to witness high growth due to growing prevalence of diabetes and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, increase in approval of injectable formulation and device, favorable reimbursement and rise in injectable cosmetic treatments. This research report categorizes and analyzes the North American injectable drug delivery technologies market under two broad segments - devices and formulations. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Injectable Drug Delivery Devices Technologies Market 5 Injectable Drug Delivery Formulation Technologies Market 6 Injectable Drug Delivery Technologies Market,By Therapeutic Applications 7 Geographic Analysis 8 Competitive Landscape 9 Company Profiles Companies Mentioned: - Antares Pharma - Baxter International - Becton, Dickinson and Company - Eli Lilly And Company - Hospira - Novo Nordisk - Sanofi - Unilife Corporation - West Pharmaceutical Services - Zogenix. For more information visit http://www.researchandmarkets.com/research/3b...th_america
Antares Pharma Announces Availability of OTREXUP (Methotrexate) Injection for Subcutaneous Use to Treat Rheumatoid Arthritis (RA) and Psoriasis in Adults, and Polyarticular Idiopathic Arthritis (pJIA) in Children
Business Wire - Wed Jan 15, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the availability of OTREXUP(TM), the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. OTREXUP was approved by the FDA in October 2013. OTREXUP is available at distribution centers throughout the USA.
Conferences, Preliminary Revenues, Board Changes, Shareholders' Meeting Results, and Clinical Trial Initiation - Research Report on Antares, Quidel, bluebird bio, Given Imaging, and Immunomedics
PR Newswire - Tue Jan 14, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Antares Pharma, Inc. (NASDAQ: ATRS), Quidel Corporation (NASDAQ: QDEL), bluebird bio, Inc. (NASDAQ: BLUE), Given Imaging Ltd. (NASDAQ: GIVN), and Immunomedics, Inc. (NASDAQ: IMMU). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Drug-Exposure Limitations of Oral Methotrexate at Doses Greater Than or Equal to 15 Mg May Be Overcome with Subcutaneous Administration
Business Wire - Thu Apr 17, 6:01AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the Annals of the Rheumatic Diseases has published results from an open-label, head-to-head randomized, crossover study comparing the relative bioavailability, safety and tolerability of OTREXUP to oral methotrexate (MTX) in adult patients with rheumatoid arthritis (RA).
Antares Pharma Announces Additional Patent Coverage for OTREXUP
Business Wire - Wed Apr 16, 6:01AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.S. Patents RE44846 and RE44847. These patents are reissued versions of U.S. Patents 7,744,582, and 7,776,015. Tracing back to inventions made in the late 1990's, the patents capture innovations in the field of auto injectors that originally established Antares Pharma's position as a leader and innovator in medical injection device technology. Importantly, these patents add protection to OTREXUP as well as Antares' pipeline products. Antares is taking steps to supplement the current Orange Book listings related to OTREXUP.
Global Insulin Delivery Devices Market to 2019
M2 - Wed Apr 09, 8:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h59w23/insulin_delivery) has announced the addition of the "Insulin Delivery Devices Market to 2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers" report to their offering. The global insulin delivery devices market was valued at $8.8 billion in 2012 and is forecast to reach $13.8 billion by 2019, at a CAGR of 7%. Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers Growth in developed economies such as the US and Europe is attributed to an increasing preference for insulin pumps and the uptake of technical advances such as artificial pancreas devices. Supply-side initiatives aim to develop artificial pancreas devices that closely mimic the pancreas by using rapid-acting insulin and multiple hormone-secreting devices for the effective control of blood glucose. The growth in developing economies is attributed to the high prevalence of diabetes and low penetration of insulin delivery devices in these countries. Collaborations among companies and research foundations such as the Juvenile Diabetes Research Foundation (JDRF) help foster innovation in the diabetes care devices market. Many of these collaborations aim to develop artificial pancreas devices that can effectively replace the pancreas, ensuring the effective management of diabetes. Emerging economies such as India and China are expected to grow at the fastest pace during the 2012-2019 forecast period. While developed economies will witness increasing uptake of technically advanced devices, emerging economies will continue to see increasing uptake for conventional insulin delivery devices such as insulin pens, due to their lower cost." Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Diabetes - Disease Overview 4 Diabetes - Epidemiology 5 Global Insulin Delivery Devices Market: Device Overview 6 Global Insulin Delivery Devices Market: Market Characterization 7 Global Insulin Delivery Devices Market: Segment Analysis and Forecasts 8 Global Insulin Delivery Devices Market: Country Analysis and Forecasts 9 Global Insulin Delivery Devices Market: Reimbursement System 10 Global Insulin Delivery Devices Market: Competitive Landscape Companies Mentioned - Abbott Laboratories - Animas - Antares Pharma - Asante Solutions - Becton, Dickinson and Company - Bioject Medical Technologies - Eli Lilly - F. Hoffmann-La Roche - Injex - Equidyne Systems - Insulet - Medtronic - Novo Nordisk (Subsidiary of Novo A/S) - Owen Mumford - Sanofi - Shanghai Fosun Pharmaceutical - Tandem Diabetes Care - Tonghua Dongbao Pharmaceutical - Ypsomed For more information visit http://www.researchandmarkets.com/research/h5...n_delivery
Technical Roundup on Health Care Sector Stocks -- Research on Becton Dickinson and Co., Antares Pharma, Hooper Holmes, and Catamaran
PR Newswire - Thu Apr 03, 7:28AM CDT
On Wednesday, April 02, 2014, the NASDAQ Composite finished at 4,276.46, up 0.20%. The Dow Jones Industrial Average closed the session at 16,573.00, up 0.24% and the S&P 500 ended the day at 1,890.90, higher by 0.29%. The gains were broad based with eight out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index finished the day at 684.15, up 0.36%, and the index has gained 7.11% in the previous three months. Investor-Edge has initiated coverage on the following equities: Becton Dickinson and Co. (NYSE: BDX), Antares Pharma Inc. (NASDAQ: ATRS), Hooper Holmes Inc. (NYSE MKT: HH) and Catamaran Corp. (NASDAQ: CTRX). Free technical research on BDX, ATRS, HH and CTRX can be downloaded upon signing up at:
Financial Results, Launches, Adjusted Conversion Rates, Upcoming Presentations, and Stock Movements - Analyst Notes on AbbVie, Chemed, Antares Pharma, Magellan Health Services, and Natus Medical
PR Newswire - Thu Apr 03, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding AbbVie Inc. (NYSE: ABBV), Chemed Corp. (NYSE: CHE), Antares Pharma Inc. (NASDAQ: ATRS), Magellan Health Services Inc. (NASDAQ: MGLN), and Natus Medical Inc. (NASDAQ: BABY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Antares Pharma secures second milestone payment from LEO Pharma following launch of OTREXUP for treating psoriasis
M2 - Thu Mar 13, 6:05AM CDT
Pharmaceutical company Antares Pharma (NasdaqCM:ATRS) said on Wednesday that it has received a second milestone payment of USD5m under its dermatology partnership with LEO Pharma.
Antares Pharma Reports Fourth Quarter and Full Year 2013 Operating and Financial Results
Business Wire - Thu Mar 13, 6:01AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the fourth quarter and full year ended December 31, 2013.
Antares Pharma Receives Second Milestone Payment from LEO Pharma in OTREXUP Collaboration
Business Wire - Wed Mar 12, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the receipt of a second milestone payment of $5 million from LEO Pharma. The milestone payment was received in connection with the launch of OTREXUP and the achievement of a specific percentage of patient lives covered by managed care organizations. To date, Antares has received $10 million in milestone payments from LEO Pharma.
Medac Pharma, Inc. Announces the Issuance of U.S. Patent for Treating Autoimmune Diseases with Concentrated Methotrexate Solutions of More Than 30 mg/ml
PR Newswire - Tue Mar 11, 9:17AM CDT
Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announces the issuance, via its parent company, medac GmbH, of U.S. patent 8,664,231 (the '231 patent) by the United States Patent and Trademark Office. The patent, entitled "Concentrated Methotrexate Solutions," is directed to a method for the treatment of inflammatory autoimmune diseases by subcutaneously administering methotrexate (MTX) at a concentration of more than 30 mg/ml.
Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry
M2 - Tue Mar 11, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qpswzp/testosterone) has announced the addition of the "Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The global and the US markets are further analyzed by the following Product Segments: - Topicals - Patches - Others Company profiles are primarily based on public domain information including company URLs. The report profiles 30 companies including many key and niche players such as: - AbbVie Inc. - Acrux Ltd. - Actavis, Inc. - Antares Pharma, Inc. - Auxilium Pharmaceuticals, Inc. - Bayer HealthCare Pharmaceuticals - Clarus Therapeutics Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview 3. Product Landscape 4. Testosterone Deficiency And Trt - An Overview 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Europe 4. Asia-Pacific 5. Latin America 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 30 (including Divisions/Subsidiaries - 36) - The United States (20) - Canada (4) - Japan (1) - Europe (7) - France (1) - Germany (1) - The United Kingdom (2) - Italy (1) - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (4) For more information visit http://www.researchandmarkets.com/research/qp...estosteron
Antares Pharma Announces LEO Pharma's Launch of OTREXUP (Methotrexate) Injection to Dermatologists for Adults with Psoriasis
Business Wire - Mon Mar 10, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced LEO Pharma's launch of OTREXUPto Dermatologists, the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Antares Pharma to Host Fourth Quarter 2013 Operating and Financial Results Conference Call
Business Wire - Thu Mar 06, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its fourth quarter 2013 financial results before the market opens on Thursday, March 13, 2014, and host a conference call shortly thereafter at 8:30 a.m. ET (Eastern Time) to discuss the results. Paul K. Wotton, Ph.D., President and Chief Executive Officer, and Robert F. Apple, EVP, Chief Financial Officer, and President of the Parenteral Products Division, will host the call.
Antares Pharma to Present at the Cowen and Company 34th Annual Healthcare Conference
Business Wire - Wed Feb 26, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 34th Annual Healthcare Conference on Wednesday March 5, 2014 at 8:00 am Eastern Time.
Today's Biggest Biotech Stories: Antares Pharma Inc., BioCryst Pharmaceuticals Inc., and Raptor Phar
George Budwell, The Motley Fool - Motley Fool - Thu Feb 20, 9:02AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! It's time to check in...
Antares Pharma Announces Positive Results from the VIBEX QuickShot Pharmacokinetic Study in Testosterone Deficient Men
Business Wire - Thu Feb 20, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from a multi-center phase 2 clinical study evaluating the pharmacokinetic profile of testosterone enanthate administered once-weekly by subcutaneous injection at doses of 50 mg and 100 mg using the VIBEX QuickShot auto injector in testosterone deficient adult males.
Antares Pharma, Inc. [ATRS] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Wed Feb 19, 9:00AM CST
What:
Antares Pharma to Participate in the 2014 RBC Capital Markets' Global Healthcare Conference
Business Wire - Wed Feb 19, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that LeRoux Jooste, Senior Vice President and General Manager Pharmaceuticals, will participate in the RBC Capital Markets' Global Healthcare Conference on Wednesday February 26, 2014 at 11:00 am Eastern Time.
2013 Report on the International North America Injectable Drug Delivery Market - Forecasts to 2017
M2 - Thu Jan 23, 5:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/3brffr/north_america) has announced the addition of the "2013 Report on the International North America Injectable Drug Delivery Market - Forecasts to 2017" report to their offering. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices. The major markets covered in this report are United States and Canada. The United States accounted for the largest market of the North American injectable drug delivery technologies market in the year 2012. However, Canada is expected to witness high growth due to growing prevalence of diabetes and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, increase in approval of injectable formulation and device, favorable reimbursement and rise in injectable cosmetic treatments. This research report categorizes and analyzes the North American injectable drug delivery technologies market under two broad segments - devices and formulations. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Injectable Drug Delivery Devices Technologies Market 5 Injectable Drug Delivery Formulation Technologies Market 6 Injectable Drug Delivery Technologies Market,By Therapeutic Applications 7 Geographic Analysis 8 Competitive Landscape 9 Company Profiles Companies Mentioned: - Antares Pharma - Baxter International - Becton, Dickinson and Company - Eli Lilly And Company - Hospira - Novo Nordisk - Sanofi - Unilife Corporation - West Pharmaceutical Services - Zogenix. For more information visit http://www.researchandmarkets.com/research/3b...th_america
Antares Pharma Announces Availability of OTREXUP (Methotrexate) Injection for Subcutaneous Use to Treat Rheumatoid Arthritis (RA) and Psoriasis in Adults, and Polyarticular Idiopathic Arthritis (pJIA) in Children
Business Wire - Wed Jan 15, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the availability of OTREXUP(TM), the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. OTREXUP was approved by the FDA in October 2013. OTREXUP is available at distribution centers throughout the USA.
Conferences, Preliminary Revenues, Board Changes, Shareholders' Meeting Results, and Clinical Trial Initiation - Research Report on Antares, Quidel, bluebird bio, Given Imaging, and Immunomedics
PR Newswire - Tue Jan 14, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Antares Pharma, Inc. (NASDAQ: ATRS), Quidel Corporation (NASDAQ: QDEL), bluebird bio, Inc. (NASDAQ: BLUE), Given Imaging Ltd. (NASDAQ: GIVN), and Immunomedics, Inc. (NASDAQ: IMMU). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
